The Nishi-Shinjuku Illumination Market Lighting Ceremony, a New Illumination in Tokyo, Held to Illuminate the Nighttime in Nishi-Shinjuku!
11.12.2024 08:00:00 CET | Business Wire | Press release
The “TOKYO NIGHTTIME PROJECT” has been launched in the Nishi-Shinjuku area of Shinjuku-ku, Tokyo, with the aim of revitalizing night tourism. The project, by collaborating with organizations in the surrounding area, enlivens nighttime in Nishi-Shinjuku, an area where tradition and innovation intersect, with light displays and other activities to create a lively atmosphere for visitors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203634601/en/
The Illuminations (Photo: Business Wire)
"Nishi-Shinjuku Illumination Market” started on November 28, 2024. On Chuo-dori Avenue along the Tokyo Metropolitan Government Building, approximately 200,000 champagne gold LED lights illuminate the street for as long as 200 meters, creating a fantastic night scene, a new illumination spot in Tokyo.
At the lighting ceremony, Judoka Hifumi Abe and Uta Abe, both from the Park24 club, appeared as guests. They pressed the light button following the countdown, and the street was enveloped in glittering champagne gold lights.
TOKYO NIGHTTIME PROJECT Overview
- Sponsor: Tokyo Nighttime Project Executive Committee
- Co-sponsor: Tokyo Metropolitan Government
-
Programs:
Nishi-Shinjuku Illumination Market
New Year's Eve countdown event "Happy New Year Tokyo 2025" - Dates: Thursday, November 28th, 2024 to Monday/National holiday, January 13th, 2025
-
TOKYO NIGHTTIME PROJECT official website
https://tokyo-nighttime-project.jp/en/ -
Nishi-Shinjuku Illumination Market Overview
In addition to the illumination, food trucks and markets will line up, selling foods and goods that give a sense of Edo culture. For details, please visit the event website https://tokyo-nighttime-project.jp/en/market/ -
New Year’s Eve Countdown event “Happy New Year Tokyo 2025” Overview
"Happy New Year Tokyo 2025” will be held on New Year's Eve to close the year, a countdown event for many people including the Tokyo residents and foreign visitors, to experience the charms of Tokyo and share the anticipation for the New Year together.
With the theme of tradition and innovation, which are the attractions of Tokyo, there will be projection mapping, live performances by Japanese drummers and DJs, and talk shows by guests. In addition, new year wishes by the participants will be projected in the form of digital ema (votive picture tablet).
For details, please visit the event website https://tokyo-nighttime-project.jp/en/countdown/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203634601/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom